Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Glaukos Corp

NYSE: GKOS · Industrial Applications and Services · 8 alerts · CIK 1192448

Share price
$244.88Close, Nov 16
Market cap
$14.5B
Shares outstanding
59.2MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Glaukos Corp filings on SEC EDGAR ↗

9:01 PM ET Form 4
Insider Selling

Glaukos President & COO Joseph E. Gilliam Sells $11.1M of Stock

Joseph E. Gilliam, President & COO, sold 44,917 shares of Glaukos Corp at $243.41 to $248.42 a share (average $246.32) in 6 transactions, worth $11.1M in total on Nov 12, 2026. Shares held after the trade: 71,602 (-0.4%).

Value
$11.1M
Shares
44,917
Average price
$246.32
Role
President & COO
Holding change
-0.4%
Trade date
Nov 12, 2026
7:01 AM ET 8-K
Investor Presentation

Glaukos Investor Presentation

Glaukos Corporation filed a formal investor presentation dated November 2026 to be used in meetings with investors and stakeholders. The presentation covers the company's strategic outlook, including the commercialization of its iDose TR and Epioxa therapies.

7:32 PM ET Form 4
Insider Selling

Glaukos Director Gilbert H. Kliman Sells $632K of Stock

Gilbert H. Kliman, Director, sold 2,500 shares of Glaukos Corp at $253.00 a share, worth $632K in total on Nov 4, 2026. Shares held after the trade: 37,406 (-6.3%).

Value
$632K
Shares
2,500
Price
$253.00
Role
Director
Holding change
-6.3%
Trade date
Nov 4, 2026
9:45 PM ET Form 4
Insider Selling

Glaukos Chief Development Officer Tomas Navratil Sells $10.6M of Stock

Tomas Navratil, Chief Development Officer, sold 44,436 shares of Glaukos Corp at $237.54 to $240.52 a share (average $238.97) in 4 transactions, worth $10.6M in total on Oct 30, 2026. Shares held after the trade: 37,328 (-14.7%).

Value
$10.6M
Shares
44,436
Average price
$238.97
Role
Chief Development Officer
Holding change
-14.7%
Trade date
Oct 30, 2026
5:22 PM ET 10-Q
Financial Results

Glaukos Q3 2026 Results: Turns Profitable, Net Income $2.02M

Glaukos Corporation reported total assets of $979.5 million as of September 30, 2026, an increase from $893.5 million at year-end 2025, driven largely by growth in cash and accounts receivable. The company remains a large accelerated filer with 59,196,870 shares of common stock outstanding as of October 26, 2026.

Key figure
Net income $2.02M
4:11 PM ET 8-K
Financial Results

Glaukos Financial Results

Glaukos Corporation reported record third-quarter 2026 net sales of $211.0 million, a 58% increase year-over-year, driven by strong performance in its U.S. Glaucoma and Corneal Health segments. The company achieved GAAP net income of $2.0 million and significantly raised its full-year 2026 revenue guidance while introducing a preliminary 2027 revenue target of $1 billion.

Term
Q3 2026

“Our record third quarter results reflect successful global execution across our key global commercial and development priorities, leaving us well positioned to sustain our strong growth momentum driven by two transformational growth drivers in iDose TR and Epioxa.”

Thomas Burns, Glaukos chairman and chief executive officer
7:08 PM ET Form 4
Insider Selling

Glaukos Chief Development Officer Tomas Navratil Sells $251K of Stock

Tomas Navratil, Chief Development Officer, sold 1,527 shares of Glaukos Corp at $163.93 to $165.60 a share (average $164.45) in 3 transactions, worth $251K in total on Oct 5, 2026. Shares held after the trade: 69,291 (-0.4%).

Value
$251K
Shares
1,527
Average price
$164.45
Role
Chief Development Officer
Holding change
-0.4%
Trade date
Oct 5, 2026
5:32 PM ET Form 4
Insider Selling

Glaukos Chief Development Officer Tomas Navratil Sells $243K of Stock

Tomas Navratil, Chief Development Officer, sold 1,453 shares of Glaukos Corp at $163.20 to $170.95 a share (average $166.91) in 6 transactions, worth $243K in total on Sep 16, 2026. Shares held after the trade: 72,437 (-0.3%).

Value
$243K
Shares
1,453
Average price
$166.91
Role
Chief Development Officer
Holding change
-0.3%
Trade date
Sep 16, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.